-
The production of medicinal materials has been reduced and the price has soared!
Time of Update: 2022-09-07
As of August 2022, in the quarterly rankings of 331 varieties (involving 431 product specifications), the provinces with a high proportion of rising varieties are mainly concentrated in Jiangsu, Jiangxi, Shaanxi, Sichuan and Zhejiang five provinces, of which Jiangsu, Jiangxi and Zhejiang are more severely affected by high temperature and drought than other provinces because they are at the end of the irrigation area in the Yangtze River Basin, and the price of varieties is rising .
-
The new indications for Merck's nine-valent HPV vaccine have been approved, and the applicable age has been extended to women aged 9-45 years
Time of Update: 2022-09-07
Professor Qiao Youlin said, "Today, the approval of the nine-valent HPV vaccine to expand the age is even more exciting, which will bring more health protection options for women of different ages in China to prevent HPV infection and reduce the risk of related diseases, and further promote China to accelerate the pace of eliminating cervical cancer.
-
In the first half of the year, more than 70% of innovative pharmaceutical companies increased their R&D investment!
Time of Update: 2022-09-07
According to the mid-year report of innovative drug companies in 2022, more than 70% of innovative drug companies have increased their R&D investment, and seven companies including BeiGene, Hengrui, Junshi Biopharmaceuticals, China Biopharmaceuticals, CSPC R&D, and Chi-Med have all invested more than 1 billion yuan .
-
The vaccine has not changed, why can the nine-valent HPV vaccine be expanded to 9-45 years old
Time of Update: 2022-09-07
” In this regard, the official website of the State Food and Drug Administration has clearly pointed out that the listing of the nine-valent HPV vaccine is based on the urgent clinical needs of drugs and the direct use of overseas clinical data for registration in China .
-
Focusing on innovation, a large number of pharmaceutical companies ushered in new growth in the first half of the year!
Time of Update: 2022-09-07
It is understood that in the first half of 2022, the sales revenue of Fangsheng Pharmaceutical Yizhi wheat cloth tablets successfully exceeded 100 million, which has exceeded the annual sales revenue of 2021, in addition, the sales revenue of innovative Chinese medicine children's Jingxing cough granules also increased by more than 800% in the same period.
-
The consolidation of the pharmaceutical market has accelerated, and another pharmaceutical company has sold off hospitals
Time of Update: 2022-09-07
Financial data show that in 2021, Chenwei Zhongde achieved operating income of about 706 million yuan and net profit of 16.
Financial data show that in 2021, Chenwei Zhongde achieved operating income of about 706 million yuan and net profit of 16.
-
Circular of the State Food and Drug Administration on The Issuance of the Catalogue of Generic Drug Reference Preparations (Batch 57) (No. 38 [2022])
Time of Update: 2022-09-07
docx After the review and determination of the Expert Committee on the Consistency Evaluation of the Quality and Efficacy of Generic Drugs of the State Drug Administration, the Catalogue of Generic Drug Reference Preparations (The Fifty-seventh Batch) is hereby released.
-
Looking for good medicine, talking about classics, Zhong Jing explained the final list of classic ambassadors in three minutes!
Time of Update: 2022-09-07
Thirty-seven elites gathered in Xixia, Henan Province, where they talked about classic and famous prescriptions at the Medical Saint Herbs Collection Office, and competed fiercely for the final qualification of the event!Enrich the schedule to help professional improvementLin Jingwei, a star lecturer of Zhongjing Academy, brought professional courses to the players in the semi-finals, introduced a number of classic famous recipes, explained the in-depth and easy-to-understand recipes, and enhanced the players' cognition of classic famous recipes .
-
National Medical Insurance Bureau: The focus of the national centralized procurement of high-value consumables is coming
Time of Update: 2022-09-07
On September 3, the National Medical Security Administration made a unified reply to the recommendations of the Fifth Session of the Thirteenth National People's Congress, revealing a lot of first-ha
-
State Food and Drug Administration: Launch electronic payment of registration fees for drugs and medical device products
Time of Update: 2022-09-07
State Food and Drug Administration August 22, 2022 According to the requirements of the Ministry of Finance on steadily promoting the general payment of electronic non-tax income, the State Food and Drug Administration decided to use the electronic payment of registration fees for drugs and medical devices.
-
With the prevention and control of myopia becoming an important part of the national health strategy, the ophthalmology industry will have great prospects
Time of Update: 2022-09-07
In recent years, the development of the ophthalmology industry has begun to accelerate as the people of our country are affected by various factors such as lifestyle changes, the increase in the use of electronic products, and the improper use of eyes .
-
In August, the executives of multinational pharmaceutical companies changed frequently, and companies were in a war for talent!
Time of Update: 2022-09-07
On August 30, AstraZeneca announced the appointment of Liu Ming as Vice President of AstraZeneca China, Head of the Lung Cancer Treatment and Tumor Immunotherapy-related Business Units of the Oncology Division, and joined the Chinese management team to directly report to AstraZeneca’s oncology business.
-
Solicit for special treatment of dental implant medical service charges and consumable prices
Time of Update: 2022-09-07
In order to implement the decisions and arrangements of the Party Central Committee and the State Council, in accordance with the requirements of the "Key Points of Correcting Unhealthy Practices in the Field of Pharmaceutical Purchase and Sales and Medical Services in 2022" jointly issued by nine ministries and commissions, the National Medical Security Administration has formed a plan based on previous investigations and soliciting industry opinions.
-
Domestic pharmaceutical equipment companies are accelerating the road to differentiated innovation!
Time of Update: 2022-09-07
It is reported that at present, there are many domestic pharmaceutical equipment with R&D strength and capital that have been increasing the investment in innovative R&D and carrying out diversified and differentiated innovations in equipment and technology to help pharmaceutical companies develop higher quality .
-
NMPA: 20 batches of drugs are unqualified→ and see foreign bodies visible in injections!
Time of Update: 2022-09-07
On August 29, 2022, the State Food and Drug Administration issued a drug sampling quality announcement, which involved a total of 20 batches of drugs produced by 9 enterprises, of which 2 batches of injection visible foreign bodies did not meet the regulations, 3 batches of chrysanthemums detected banned pesticide residues, 7 batches of comfrey did not meet the regulations, and risk control measures such as suspension of sales and use and recall of the above drugs have been taken.
-
What is the difference between a beautiful pupil and contact lenses? Will it fade? Is wearing it harmful to the eyes for a long time?
Time of Update: 2022-09-07
Chen Zhanbiao, director of the Department of Ophthalmology of Fuzhou First Hospital: This (case) is also after wearing a beautiful pupil, there is red eye pain, fear of light and tears, foreign body sensation, and decreased vision.
-
In 5 years, cross-border transactions between local pharmaceutical companies and overseas pharmaceutical companies increased by 300%
Time of Update: 2022-09-07
On May 5, Lixin Pharmaceutical licensed the innovative antibody-conjugated drug (ADC) LM-302 independently developed by Lixin Pharmaceutical to Turning Point corporation in the United States; On April 6, HeboMed announced that it had entered into a global external licensing agreement with AstraZeneca to develop and commercialize HBM7022.
-
CIFTIS Opens International Consumption Day of Traditional Chinese Medicine to Explore Inheritance, Innovation and Development
Time of Update: 2022-09-07
The Beijing Municipal Administration of Traditional Chinese Medicine and the Beijing Intellectual Property Office jointly released the Action Plan for Strengthening the Foundation of Intellectual Property Rights of Traditional Chinese Medicine in Beijing, which will help consolidate the foundation of Beijing's traditional Chinese medicine intellectual property work, stimulate the innovation and creativity of the medical and health industry, and protect and stimulate scientific research.
-
Announcement on the time of the "88th API China & 26th CHINA-PHARM"
Time of Update: 2022-09-07
The second China Pharmaceutical CXO Conference and nearly 30 wonderful conferences will be held at the same time of the exhibition, and we look forward to meeting you again!Dear exhibitors, visitors and friends in the industry: In view of the recent spread and frequent outbreak of the new crown pneumonia epidemic, the situation is complex and changeable.
-
From October 20, 279 proprietary Chinese medicines in Hunan Province will reduce prices! There are varieties down to less than 1 yuan
Time of Update: 2022-09-07
In addition to the amount of procurement agreed, medical institutions may purchase unselected drugs with appropriate prices according to clinical needs, and the purchase amount of all drugs (including selected drugs and non-selected drugs) in the collection catalogue of proprietary Chinese medicines shall not exceed 85% of the same period of the previous year.
